PHARMAJET Stock
PharmaJet's devices provide for fixed dose needle-free jet injection for all three tissue depths (IM, SC, & ID).
Sign up today and learn more about PHARMAJET Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About PHARMAJET Stock
PharmaJet is a user-friendly, inexpensive device for fluid injection into the body without a needle. Able to compete with traditional needle-syringe delivery, which inherently poses costly needle-stick, re-use and pass-along disease risk, the technology creates a positive ROI back for every injection. Unique in the field of jet injection because of its ability to reach all target tissues (IM, SC--0.5 mL, and ID--0.1 mL) accurately and comfortably, supported by wide regulatory claims (global and country specific) PharmaJet's platforms are the only commercially available devices that effectively address the 3 B annual immunization market. In addition to standard depth and dose delivery of any fluid, PharmaJet also has the ability to hyper-stimulate an improved immune response. The intradermal platform reduces the dose of vaccine by 60-80%, delivering into a 1.5-3mm tissue space in less than 1/10th of a second and achieving the same or superior immune response to a full intramuscular dose. For nucleic acid vaccines, both device platforms provide rapid delivery that helps negate the need for electroporation, while providing a several fold improved immune response versus needle based delivery. This is helping to facilitate vaccines gaining regulatory approval for solutions to pandemic threats and cancer vaccines, with a simple push and click.
Funding History
March 2011 | $4.2M |
---|---|
November 2011 | $3.4M |
August 2012 | $2.8M |
April 2013 | $2.5M |
July 2013 | $5.2M |
June 2015 | $3.8M |
January 2016 | $3.0M |
June 2017 | $3.0M |
February 2018 | $0 |
January 2019 | $5.0M |
Management
Vice-Chairman, Global Business Development Officer, Co-Founder
Heather Callender-Potters
Chairman and Chief Executive Officer
Ron Lowy
CFO
Jeffrey Jordan
Chief Operating Officer
Chris Cappello
Press
patents - Apr, 14 2024
Needle-less injector and method of fluid deliverypatents - Apr, 14 2024
Needle-free intradermal injection devicepatents - Apr, 14 2024
Needle-Free Injectorbusinesswire - Apr, 7 2024
PharmaJet Announces Scientific Advisory Boards and Presentation at World Vaccine Congress in Washington on April 1artrocker - Jan, 29 2024
Intramuscular Injector Market Growing Rapidly by-Antares ...